|
TATDN3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6251444634463E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.4267999999994E-05 |
| Normal-vs-Stage3 |
4.34130509319175E-11 |
| Normal-vs-Stage4 |
8.8911999984731E-08 |
| Stage1-vs-Stage2 |
3.609800E-02 |
| Stage1-vs-Stage3 |
6.998400E-01 |
| Stage1-vs-Stage4 |
9.888400E-01 |
| Stage2-vs-Stage3 |
9.821600E-02 |
| Stage2-vs-Stage4 |
1.371440E-01 |
| Stage3-vs-Stage4 |
8.056800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.33066907387547E-16 |
| Normal-vs-AfricanAmerican |
2.587000E-04 |
| Normal-vs-Asian |
6.55919762948542E-11 |
| Caucasian-vs-AfricanAmerican |
1.236200E-01 |
| Caucasian-vs-Asian |
8.774600E-01 |
| AfricanAmerican-vs-Asian |
1.568970E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.25479995469891E-09 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
1.173990E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
3.10862446895044E-15 |
| Normal-vs-Age(61-80Yrs) |
3.19689999994655E-06 |
| Normal-vs-Age(81-100Yrs) |
6.042500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.716000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.393400E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.836950E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.983000E-03 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.217800E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.164200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.327030E-01 |
| Classical-VS-Follicular |
1.786300E-02 |
| Classical-VS-Other |
8.540000E-01 |
| Classical-VS-Normal |
1.62858615482264E-12 |
| Tall-VS-Follicular |
1.959980E-03 |
| Tall-VS-Other |
2.962400E-01 |
| Tall-VS-Normal |
9.64950341852955E-11 |
| Follicular-VS-Other |
5.726400E-01 |
| Follicular-VS-Normal |
5.99050000049672E-07 |
| Other-VS-Normal |
3.901400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.18602913548693E-13 |
| Normal-vs-N1 |
1.56541446472147E-14 |
| N0-vs-N1 |
2.141900E-02 |
|
|
